Parallel Advisors’s Taysha Gene Therapies TSHA Stock Holding History

Parallel Advisors’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.36K	Hold	280	–	–	﹤0.01%	3718
2026 Q2	$1.91K	Sell	280 -6	-2%	-$36	﹤0.01%	3528
2026 Q1	$1.28K	Buy	286 +6	+2%	+$28	﹤0.01%	3490
2025 Q4	$1.54K	Hold	280	–	–	﹤0.01%	3204
2025 Q3	$916	Hold	280	–	–	﹤0.01%	3241
2025 Q2	$647	Hold	280	–	–	﹤0.01%	3271
2025 Q1	$389	Hold	280	–	–	﹤0.01%	3277
2024 Q4	$484	Hold	280	–	–	﹤0.01%	3228
2024 Q3	$563	Hold	280	–	–	﹤0.01%	3163
2024 Q2	$627	Buy	+280	New	+$815	﹤0.01%	3051
2022 Q1	–	Sell	-45	Closed	-$1K	–	3277
2021 Q4	$1K	Buy	+45	New	+$679	﹤0.01%	2971

Other funds holding TSHA

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Quantum Private Wealth Tampa, Florida $391M AUM 50.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

Privium Fund Management Amsterdam, Netherlands $516M AUM 18.66% 1-Year Est. Return

Chicago Partners Investment Group Chicago, Illinois $5.45B AUM 19.52% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

Parallel Advisors's TSHA Position: Q3 2026 in Review

Parallel Advisors held its Taysha Gene Therapies (TSHA) position steady in Q3 2026 at 280 shares worth $1.36K. The position accounts for ﹤0.01% of the portfolio, ranked #3718.

Parallel Advisors first reported a position in TSHA in Q4 2021 and has held it in 11 quarters since. The position peaked at $1.91K in Q2 2026. 49 funds tracked by Wall St. Rank hold TSHA as of Q3 2026.

Parallel Advisors held 280 shares of Taysha Gene Therapies worth $1.36K as of Q3 2026.
Parallel Advisors left its Taysha Gene Therapies share count unchanged in Q3 2026.
Taysha Gene Therapies made up ﹤0.01% of Parallel Advisors's portfolio in Q3 2026, its #3718 holding.
Parallel Advisors first reported a position in Taysha Gene Therapies in Q4 2021 and has held it in 11 quarters since.
Parallel Advisors's Taysha Gene Therapies position peaked at $1.91K in Q2 2026.
49 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q3 2026.

Based on Parallel Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.